These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10220617)

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: an industry perspective.
    Marshall PR
    Am Heart J; 1999 May; 137(5):S138-41. PubMed ID: 10220617
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: a health system perspective.
    Ahmad M
    Am Heart J; 1999 May; 137(5):S142-4. PubMed ID: 10220618
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective.
    Cohen DJ
    Am Heart J; 1999 May; 137(5):S133-7. PubMed ID: 10220616
    [No Abstract]   [Full Text] [Related]  

  • 4. Should use of intracoronary stents during percutaneous revascularisation be restricted?
    Palmer N; Fort S; Starkey I; Shaw T; Northridge D
    Lancet; 1998 Feb; 351(9100):416-7. PubMed ID: 9482299
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 6. Funding of coronary angioplasty and coronary stenting in public hospitals.
    Harper RW
    Aust N Z J Med; 1996 Feb; 26(1):3-4. PubMed ID: 8775519
    [No Abstract]   [Full Text] [Related]  

  • 7. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCI and stable coronary heart disease--COURAGE to change our minds?
    Kakafika AI; Mikhailidis DP; Wierzbicki AS; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2007 Jul; 5(3):173-4. PubMed ID: 17627560
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
    Polanczyk CA; Wainstein MV; Ribeiro JP
    Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of interventional cardiac procedures.
    Mark DB
    J Interv Cardiol; 1994 Aug; 7(4):369-78. PubMed ID: 10151067
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.
    Cohen DJ; Breall JA; Ho KK; Kuntz RE; Goldman L; Baim DS; Weinstein MC
    Circulation; 1994 Apr; 89(4):1859-74. PubMed ID: 8149551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common sense, dollars and cents, and drug-eluting stents.
    Vaitkus PT
    J Am Coll Cardiol; 2006 Jul; 48(2):268-9. PubMed ID: 16843173
    [No Abstract]   [Full Text] [Related]  

  • 13. PCI or CABG: which patients and at what cost?
    Gershlick T; Thomas M
    Heart; 2007 Oct; 93(10):1188-90. PubMed ID: 17890695
    [No Abstract]   [Full Text] [Related]  

  • 14. Economics and outcomes of coronary stenting: are stents right for everybody?
    Weintraub WS
    J Invasive Cardiol; 2000 Apr; 12(4):200-2. PubMed ID: 10785673
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic evaluation of sirolimus-eluting stents.
    Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
    CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coronary angioplasty: use and cost].
    Bossi I; De Servi S; Bramucci E; Angoli L
    G Ital Cardiol; 1997 May; 27(5):489-94. PubMed ID: 9244756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of drug-eluting stents: real-world scrutiny of the BASKET trial of real-world usage.
    Cooper LM; Linde-Zwirble W
    Expert Opin Drug Deliv; 2006 May; 3(3):305-9. PubMed ID: 16640492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 19. Are drug-eluting stents cost-effective when compared with bare-metal stents in a real-world setting?
    Moussa I
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):192-3. PubMed ID: 16568127
    [No Abstract]   [Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
    Anderson KM; Bala MV; Weisman HF
    Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.